STeadfast: Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients

Sponsor

Sangamo Therapeutics (Industry)

Overall Status

Recruiting

CT.gov ID

NCT04817774

Collaborator

(none)

Enrollment

Locations

Arms

59.6

Anticipated Duration (Months)

10.5

Patients Per Site

0.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the safety and tolerability of TX200-TR101 and its effects on the donated kidney in living donor kidney transplant recipients. TX200-TR101 is a product made from a kidney transplant recipient's own immune cells, which are genetically modified and designed to help the transplant recipient's body accept their donated kidney and prevent their immune system from rejecting it.

Condition or Disease	Intervention/Treatment	Phase
Kidney Transplant Rejection End Stage Renal Disease	Biological: TX200-TR101	Phase 1/Phase 2

Detailed Description

This is a multicentre, first-in-human, open-label, single ascending dose, dose-ranging study of autologous, chimeric antigen receptor T regulatory cells (CAR-Treg) in HLA-A2 mismatched living donor kidney transplant recipients, with a control cohort of mismatched kidney transplant recipients of similar immunological risk.The aim is for the CAR-Tregs to recognise the HLA-A2 molecule present on the donated kidney and subsequently induce and maintain immunological tolerance to the organ.

The study requires three different types of participants - transplant recipients who will receive the study treatment TX200-TR101; control participants, who are transplant recipients who will not receive the study treatment; and transplant donors, who will donate their kidney to the transplant recipients.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

42 participants

Allocation:

Non-Randomized

Intervention Model:

Sequential Assignment

Masking:

None (Open Label)

Primary Purpose:

Prevention

Official Title:

Multicentre Open-Label Single Ascending Dose Dose-Ranging Phase I/IIa Study to Evaluate Safety and Tolerability of an Autologous Antigen-Specific Chimeric Antigen Receptor TRegulatory Cell Therapy in Living Donor Renal Transplant Recipients

Actual Study Start Date :

Mar 17, 2021

Anticipated Primary Completion Date :

Nov 13, 2024

Anticipated Study Completion Date :

Mar 4, 2026

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Treatment group Subjects undergo kidney transplant as per planned standard of care and are administered study drug post transplantation, up to 15 subjects.	Biological: TX200-TR101 TX200-TR101 is an autologous gene therapy medicinal product composed of Treg cells (CD4+/CD45RA+/CD25+/CD127low/neg) that have been ex vivo expanded and transduced with a lentiviral vector encoding for a CAR to recognize HLA-A*02. Treatment will be given via an IV infusion at a pre-defined timepoint several weeks after transplant. Three, single ascending dose cohorts of TX200-TR101 are planned and an additional expansion cohort. Other Names: CAR-Tregs
No Intervention: Control group and Transplant donors Control group: Subjects undergo kidney transplant as per planned standard of care with no study drug administered, up to 6 subjects. Transplant donors: Transplant donors for each subject in the treatment and control groups, up to 21 subjects.

Arm

Intervention/Treatment

Experimental: Treatment group

Subjects undergo kidney transplant as per planned standard of care and are administered study drug post transplantation, up to 15 subjects.

Biological: TX200-TR101

TX200-TR101 is an autologous gene therapy medicinal product composed of Treg cells (CD4+/CD45RA+/CD25+/CD127low/neg) that have been ex vivo expanded and transduced with a lentiviral vector encoding for a CAR to recognize HLA-A*02. Treatment will be given via an IV infusion at a pre-defined timepoint several weeks after transplant. Three, single ascending dose cohorts of TX200-TR101 are planned and an additional expansion cohort.

Other Names:

CAR-Tregs

No Intervention: Control group and Transplant donors

Control group: Subjects undergo kidney transplant as per planned standard of care with no study drug administered, up to 6 subjects. Transplant donors: Transplant donors for each subject in the treatment and control groups, up to 21 subjects.

Outcome Measures

Primary Outcome Measures

Safety and Tolerability [28 days post infusion]
Safety and tolerability of TX200-TR101 infusion evaluated by incidence and grade of treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs) according to CTCAE V5.0.

Secondary Outcome Measures

Acute graft related outcomes [Day of infusion through to Week 84]
Incidence of biopsy confirmed acute rejection according to the Banff classification criteria
Long-term safety [Day of infusion through to Week 84]
Number of transplant recipient subjects with TEAEs, including SAEs, as assessed by CTCAE v5.0
Immunosuppression [Day of infusion through to Week 84]
Ability to reduce immunosuppression as measured by the proportion of subjects receiving tacrolimus monotherapy at Week 84
Graft localization [Day of infusion through to Week 84]
Graft localization of TX200-TR101 cells as measured by the presence of CD4+ CAR+ cells in the renal transplant biopsy
Chronic graft related outcomes [Day of infusion through to Week 84]
Chronic graft dysfunction as measured by estimated glomerular filtration rate
Chronic graft related outcomes [Day of infusion through to Week 84]
Incidence of chronic graft rejection according to the Banff criteria for chronic rejection

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 70 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Written informed consent.
Male or female aged 18 - 70 years.
Diagnosis of End Stage Renal Disease and waiting for a new kidney from an identified live donor.
Subjects who will be single organ recipients (kidney).
Able and willing to use contraception.

Exclusion Criteria:

HLA identical to the donor.
Subjects with prior organ transplant.
Known hypersensitivity to study medication ingredients, protocol defined immunosuppressive medications, or a significant allergic reaction to any drug.
Positive serology for human immunodeficiency virus (HIV) or syphilis, active or occult hepatitis B virus (HBV), active hepatitis C virus (HCV) infection, or other clinically active local or systemic infection.
Subjects who are Epstein-Barr Virus (EBV) seronegative.
Positive flow cytometric crossmatch using donor lymphocytes and recipient serum.
Subjects with panel-reactive antibody (PRA) >20% within 6 months prior to enrolment.
Subjects with current or recent donor-specific antibodies.
Use of any experimental medicinal product within 3 months.
Current use of systemic immunosuppressive agents
Significant unstable or poorly controlled acute or chronic diseases (except ESRD), limited life expectancy, clinically relevant central nervous system pathology, history of drug/alcohol abuse or psychiatric disorder or other condition that is not compatible with adequate study follow-up, history of malignancy in the past 5 years and any other reason that, in the opinion of the Site Investigator or Medical Monitor, would render the subject unsuitable for participation in the study.
Subjects with abnormal laboratory values in the following parameters:
Haemoglobin
Platelets
White blood cells
Aspartate transaminase (AST) and or alanine transaminase (ALT)
Total bilirubin

Contacts and Locations

Locations

	Site	City	Country	Postal Code
1	University Hospitals Leuven	Leuven	Belgium
2	University Medical Center Groningen	Groningen	Netherlands
3	Erasmus MC, University Medical Center	Rotterdam	Netherlands	3015 CN
4	Oxford University Hospitals NHS Foundation Trust,	Oxford	United Kingdom